Klebsiella pneumoniae Carbapenemase–2 in Argentina
Author Information
Author(s): Pasteran Fernando G., Otaegui Luis, Guerriero Leonor, Radice Gabriel, Maggiora Ricardo, Rapoport Melina, Faccone Diego, Di Martino Ana, Galas Marcelo
Primary Institution: Instituto Nacional de Enfermedades Infecciosas–ANLIS “Dr. Carlos G. Malbran,” Ciudad Autónoma de Buenos Aires, Argentina
Hypothesis
The study investigates the emergence of KPC-2 producing Klebsiella pneumoniae and Citrobacter freundii clinical isolates in Argentina.
Conclusion
The study identified KPC β-lactamase in two strains from one patient in Argentina, highlighting the potential for misidentification of resistance due to cross-reactions.
Supporting Evidence
- K. pneumoniae carbapenemase-1 was first detected in 2001 in North Carolina.
- Carbapenem resistance has been identified among 77 Klebsiella pneumoniae isolates in Argentina since 1995.
- Both clinical isolates produced several beta-lactamases, including KPC.
- Conjugation resulted in the transfer of resistance to a wild-type Salmonella isolate.
Takeaway
Doctors found a type of bacteria in Argentina that can resist a strong medicine called carbapenem, which can make treating infections harder.
Methodology
The study used disk diffusion and MIC testing to determine antibiotic resistance and characterized beta-lactamases by PCR.
Limitations
The study may not represent all cases of KPC in Argentina due to the limited sample size.
Participant Demographics
A 36-year-old woman with systemic lupus erythematosus and chronic renal failure.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website